Peregrine Pharmaceuticals (PPHM) Price Target Nearly Doubled

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

After rising 47 percent Friday on positive trial results, shares of Peregrine Pharmaceuticals (NASDAQ: PPHM) are tacking on another 9 percent in pre-open trading Monday after Roth Capital boosted its price target from $5 to $9. The firm also reiterated its Buy rating.

For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.

Shares of Peregrine Pharmaceuticals closed at $4.50 yesterday, with a 52 week range of $0.39-$5.08.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
• Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change, Momentum Movers

Related Entities

Roth Capital

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?